How nitrosamine contamination is transforming pharmaceutical quality control standards
By
Kiran Kumar Kurella, special to C&EN
Summary
The article discusses how nitrosamine contamination discovered in 2018 in angiotensin receptor blocker medicines has fundamentally transformed pharmaceutical quality control. What began as a crisis with global recalls and regulatory investigations has evolved into a defining benchmark for the pharmaceutical sector. The contaminants, once viewed as anomalies, are now catalyzing a sea change in how the industry approaches quality assurance and impurity testing.
Source
Key quotes
· 3 pulledA pharmaceutical quality crisis involving nitrosamine contamination began in 2018 with the discovery of N-nitrosodimethylamine, a type of nitrosamine, in angiotensin receptor blocker medicines, triggering global recalls, regulatory investigations
Once viewed as anomalies, the contaminants have become a defining benchmark for the pharmaceutical sector
Nitrosamines are catalyzing a sea change in pharma quality control
You might also wanna read
Radioactive Contamination in Shrimp Traced to Indonesian Steel Manufacturer
Indonesian authorities have traced radioactive contamination in shrimp and spices to a steel manufacturer, Peter Metal Technology (PMT), in

New rules for safer and more sustainable detergents
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure
This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont
EU-banned pesticide residues found in imported rice, tea and spices across four European countries
Laboratory tests on 64 food products from four EU countries (Netherlands, France, Austria, Germany) found residues of pesticides that are no
Investigation finds over 450 instances of apparent data manipulation in Thermo Fisher antibody catalog
An investigation by Sholto David reveals widespread apparent data manipulation in Thermo Fisher Scientific's antibody catalog. More than 450

Comments
Sign in to join the conversation.
No comments yet. Be the first.